GSK (LON:GSK) Given Sector perform Rating at Royal Bank Of Canada

GSK (LON:GSK)‘s stock had its “sector perform” rating restated by equities researchers at Royal Bank Of Canada in a report released on Tuesday, Digital Look reports. They presently have a GBX 1,975 target price on the stock. Royal Bank Of Canada’s price target indicates a potential upside of 9.57% from the stock’s previous close.

Several other research firms have also recently commented on GSK. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Wednesday, September 2nd. Two investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GSK currently has an average rating of “Hold” and an average price target of GBX 2,039.38.

GSK Price Performance

GSK opened at GBX 1,802.50 on Tuesday. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73. The stock has a market capitalization of £72.23 billion, a P/E ratio of 15.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. The company’s 50 day simple moving average is GBX 1,913.92 and its 200-day simple moving average is GBX 1,975.65. GSK has a one year low of GBX 1,455 and a one year high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The company reported GBX 10.80 earnings per share for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Transactions at GSK

In other news, insider Jeannie Lee purchased 802 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of GBX 5,069 per share, for a total transaction of £40,653.38. Also, insider Jonathan Symonds acquired 1,550 shares of GSK stock in a transaction that occurred on Friday, June 19th. The shares were purchased at an average cost of GBX 1,935 per share, for a total transaction of £29,992.50. In the last ninety days, insiders purchased 3,618 shares of company stock worth $13,481,942. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.